Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Q-Plex™ Human C-Peptide

  • Regulatory status:RUO
  • Type:Singleplex Assays
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

462849HU 96 wells (1 kit)
PubMed Product Details
Technical Data

Cat # changed from RQS462849HU to 462849HU


Singleplex Assays


Serum, Plasma, Cell culture supernatant

Sample Requirements

50 µl/well


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date.

Calibration Range

39–0.16 ng/ml

Limit of Detection

0.1 ng/ml



  • For research use only
  • Detection Method: Chemiluminescent
  • This kit is validated for use with plasma, serum, and cell culture supernates

Research topic

Diabetology - Insulin, C-Peptide, Proinsulin


The Q-Plex™ Human C-Peptide Kit is a fully quantitative ELISA. The assay measurement is achieved by placing two spots consisting of capture antibodies in a defined array to the bottom of each well of a 96-well plate. Along with the assay spots, there is one positive control spot for assuring proper assay procedure and for software overlay placement. High quality reagents help ensure the accuracy and precision of your results.

Using less than 50 μL of sample per well, up to 80 samples can be assayed for a single assay within 2.5 hours. The array design of the singleplex kit, allows the user to have intra-well replicates for additional statistical data. The Q-Plex™ Human C-Peptide ELISA provides researchers an easy to use and cost effective means of generating data for each sample.

Summary References (10)

References to C-Peptide

  • Beischer W, Heinze E, Keller L, Raptis S, Kerner W, Pfeiffer EF. Human C-peptide. Part II: Clinical studies. Klin Wochenschr. 1976 Aug 1;54 (15):717-25
  • Beischer W, Keller L, Maas M, Scherfer E, Pfeiffer EF. Human C-peptide. Part I: Radioimmunoassay. Klin Wochenschr. 1976 Aug 1;54 (15):709-15
  • Blix PM, Boddie-Willis C, Landau RL, Rochman H, Rubenstein AH. Urinary C-peptide: an indicator of beta-cell secretion under different metabolic conditions. J Clin Endocrinol Metab. 1982 Mar;54 (3):574-80
  • Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci. 1984;19 (4):297-352
  • Conget I, Gonzalez-Clemente JM, Casals E, Casamitjana R, Gomis R, Malaisse WJ. Effect of hyperlipacidemia on plasma C-peptide concentration during euglycemic hyperinsulinemic clamp. Diabetes Res. 1993;22 (1):41-8
  • Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 1975 Jun;55 (6):1278-83
  • Krew MA, Kehl RJ, Thomas A, Catalano PM. Relation of amniotic fluid C-peptide levels to neonatal body composition. Obstet Gynecol. 1994 Jul;84 (1):96-100
  • Rendell M. C-peptide levels as a criterion in treatment of maturity-onset diabetes. J Clin Endocrinol Metab. 1983 Dec;57 (6):1198-206
  • Rubenstein AH, Steiner DF, Horwitz DL, Mako ME, Block MB, Starr JI, Kuzuya H, Melani F. Clinical significance of circulating proinsulin and C-peptide. Recent Prog Horm Res. 1976;33:435-75
  • Tropeano G, Lucisano A, Liberale I, Barini A, Vuolo IP, Martino G, Menini E, Dell'Acqua S. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 1994 Feb;78 (2):305-9
Related Products Docs